EOCN EoCene Ltd.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1595353 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026-06-30), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-30.1%
TTM EPS YoY-182.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-68.2%
ROA-55.0%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets30.3%
Debt / equity0.00x
Current ratio4.16x
Interest coverage—
Cash quality & payout
Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026-06-302026-06-30 | 2026-03-312026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $1.78M | — | $2.10M | $1.09M | $1.06M | — | $1.07M | $738,000 |
| SG&A expense | $993,000 | — | $946,000 | $1.01M | $1.05M | — | $572,000 | $1.27M |
| Net income | -$2.72M | -$1.91M | -$4.82M | -$1.89M | -$2.50M | -$1.10M | -$3.21M | -$1.91M |
| EPS (basic) | 2.86 | — | — | 0.33 | 5.06 | — | — | 2.31 |
| EPS (diluted) | 2.86 | — | — | 0.33 | 5.06 | — | — | 2.31 |
| Weighted avg. shares (diluted) | 952,168 | — | — | 5.46M | 493,524 | — | — | 829,500 |
| Balance sheet | ||||||||
| Cash & equivalents | $2.88M | — | $3.98M | $3.31M | $4.96M | — | $4.65M | — |
| Short-term investments | $5.88M | — | $7.03M | $8.18M | $8.10M | — | $7.18M | — |
| Receivables | — | — | — | — | — | — | $672,000 | — |
| Current assets | $11.71M | — | $18.63M | $19.72M | $21.08M | — | $16.12M | — |
| PP&E, net | $48,000 | — | — | — | — | — | — | — |
| Goodwill | $1.76M | — | — | — | — | — | — | — |
| Total assets | $18.28M | — | $18.63M | $21.58M | $22.94M | — | $18.50M | — |
| Current liabilities | $2.81M | — | $2.85M | $2.47M | $2.42M | — | $2.17M | — |
| Total liabilities | $5.54M | — | $2.85M | $2.47M | $2.42M | — | $2.17M | — |
| Shareholders' equity | $12.74M | $13.95M | $15.78M | $19.11M | $20.52M | $16.88M | $16.33M | $18.44M |
| Shares outstanding | 1.00M | — | 822,674 | 5.48M | 5.30M | — | 1.66M | — |
| Cash flow statement | ||||||||
| Operating cash flow | — | — | -$1.95M | -$1.94M | — | — | -$1.91M | -$1.12M |
| Investing cash flow | — | — | $1.43M | -$3,000 | — | — | -$2.45M | -$486,000 |
| Financing cash flow | — | — | $1.19M | $289,000 | — | — | $448,000 | — |
| Depreciation & amortization | — | — | — | — | — | — | $0 | $0 |
| Stock-based compensation | — | — | $240,000 | $105,000 | — | — | $116,000 | $132,000 |
Free plan shows the latest 8 periods; Pro shows all 25 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.